HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer

HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer

Abstract Many targeted cancer therapies rely on biomarkers assessed by scoring of immunohistochemically (IHC)-stained tissue, which is subjective, semiquantitative, and does not account for expression heterogeneity. We describe an image analysis-based method for quantitative continuous scoring (QCS)...

Full description

Bibliographic Details
Main Authors: Ansh Kapil, Andreas Spitzmüller, Nicolas Brieu, Susanne Haneder, Anatoliy Shumilov, Armin Meier, Fabiola Cecchi, Alice Barkell, Nathalie Harder, Katrin Mittermaier, Ana Hidalgo-Sastre, Regina Alleze, Markus Schick, Günter Schmidt, Hadassah Sade, Zenta Tsuchihashi, Fumitaka Suto, Mark Gustavson, J. Carl Barrett, Danielle Carroll
Format: Article
Language:English
Published: Nature Portfolio 2024-05-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-024-61957-9

Internet

https://doi.org/10.1038/s41598-024-61957-9

Similar Items